# US 2019/0169257 A1 · Acylated derivative of human insulin or analogue thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0169257 A1
- Document ID: US20190169257A1
- Status: Published application
- Kind: A1
- Application number: 16/320,997
- Filed: 2017-08-01
- Published: 2019-06-06
- Earliest claimed: 2016-08-02
- Assignees: Jiangsu Hengrui Medicine Co., Ltd.
- Applicants: Jiangsu Hengrui Medicine Co., Ltd.
- Inventors: Deyu LIU; Hongwei WANG; Liang ZHAO; Feifei WANG; Xiang ZENG; Tao WANG; Yali WANG; Yulu DAI
- Web page: https://patentgrep.com/patent/US20190169257A1

## CPC

- C07K 14/62: Insulins
- A61K 38/28: Insulins
- A61K 47/542: {Carboxylic acids, e.g. a fatty acid or an amino acid}
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- C07K 1/06: using protecting groups or activating agents {(C07K1/003, C07K1/006 take precedence)}
- C07K 1/107: by chemical modification of precursor peptides
- Y02P 20/55: Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

Provided is an acylated derivative of human insulin or an analogue thereof. Specifically disclosed is an acylated derivative of a human insulin analogue, or zinc complex thereof; said acylated derivative is longer-lasting than existing insulin analogues and acylated derivatives thereof, its blood glucose reduction is more steady, and it is more stable in storage.

## Claims

### Claim 1

An acylated derivative of human insulin analogue or a zinc complex thereof, wherein the acylated derivative of human insulin analogue has a structure represented by the following formula:
S—W—X—Y—Z (I)
wherein S is human insulin in which threonine at amino acid 30 on B chain is absent; and
—W—X—Y—Z is an acylated modifying group of insulin analogue;
wherein W is a diacyl structure having —OC(CH2)nCO—, wherein n is an integer between 2 and 10, and an amide bond is formed by one of said diacyl structure's acyl groups with α-amino group of the amino acid residue at N-end of A-chain or B-chain of parent insulin or analogue thereof or with ε-amino group of lysine residue present on B-chain;
X is a diamino compound containing carboxylic acid group, and an amide bond is formed by linking one of the amino groups of the compound to one of the acyl groups in W;
Y is -A(CH2)m—, wherein m is an integer between 6 and 32, preferably an integer between 10 and 16, particularly preferably an integer between 12 and 14, and A is absent or CO—; and
Z is —COOH.

### Claim 2 (depends on 1)

The acylated derivative of human insulin analogue or a zinc complex thereof according to claim 1, wherein the amide bond is formed by W with the ε-amino group of lysine residue present on B-chain.

### Claim 3 (depends on 1)

The acylated derivative of human insulin analogue or a zinc complex thereof according to claim 1, wherein n is an integer between 2 and 5, preferably 2.

### Claim 4 (depends on 1)

The acylated derivative of human insulin analogue or a zinc complex thereof according to claim 1, wherein X is —HN(CH2)pCH(COOH)NH—, wherein p is an integer between 2 and 10, preferably an integer between 2 and 6, particularly preferably an integer between 2 and 4, most preferably 4.

### Claim 5 (depends on 1)

The acylated derivative of human insulin analogue or a zinc complex thereof according to claim 1, wherein —W—X—Y—Z has a structure shown as the following:
preferably is

### Claim 6

Nα—(HOOC(CH2)14CO)—Nε—(OCCH2CH2CO—(NεB29-Des(B30) human insulin))-Lys-OH or a zinc complex thereof, preferably lysine B29 (Nε—(Nα-hexadecane diacid-L-lysine-M-oxobutyryl))des(B30) human insulin or a zinc complex thereof.

### Claim 7 (depends on 1)

A method for preparing the acylated derivative of human insulin analogue or a zinc complex thereof according to claim 1, comprising a step of reacting a compound of formula (III) with human insulin in which threonine at amino acid 30 on B chain is absent, wherein the compound of formula (III) is:
R—W—X—Y—Z (III)
wherein R is a leaving group, preferably an activated ester group, more preferably selected from the group consisting of

### Claim 8 (depends on 7)

The method according to claim 7, further comprising a step of removing carboxyl protecting group from a compound of formula (III′) to obtain the compound of formula (III), wherein the compound of formula (III′) is:
wherein X′ and Z′ are X and Z protected by a protecting group at each carboxyl group, wherein said protecting group is preferably C1-C6 alkyl group, preferably C1-C4 alkyl group, and particularly preferably methyl or tert-butyl.

### Claim 9 (depends on 1)

A compound of formula (III),
R—W—X—Y—Z (III)
wherein W, X, Y and Z are as defined in claim 1, and
R is a leaving group, preferably an activated ester group, more preferably selected from the group consisting of

### Claim 10 (depends on 9)

A compound of formula (III′) obtained by subjecting every carboxyl group in X and Z of the compound of formula (III) according to claim 9 to carboxyl protection,
R—W—X′—Y—Z′ (III′)
wherein X′ and Z′ are X and Z protected by a protecting group at each carboxyl group, wherein said protecting group is preferably C1-C6 alkyl group, preferably C1-C4 alkyl group, particularly preferably methyl or tert-butyl.

### Claim 11 (depends on 9)

The compound according to claim 9, wherein the compound is
preferably

### Claim 12 (depends on 1)

The zinc complex of the acylated derivative of human insulin analogue according to claim 1, wherein more than 4 zinc atoms are contained in every 6 acylated insulin molecules.

### Claim 13 (depends on 1)

A pharmaceutical composition comprising the acylated derivative of human insulin analogue or a zinc complex thereof according to claim 1, and a pharmaceutically acceptable carrier.

### Claim 14 (depends on 13)

The pharmaceutical composition according to claim 13, further comprising fast-acting insulin.

### Claim 15

(canceled)

### Claim 16

(canceled)

### Claim 17 (depends on 1)

A method for treating diabetes comprising administering to a patient in need thereof the acylated derivative of human insulin analogue or a zinc complex thereof according to claim 1.

### Claim 18 (depends on 1)

A method for treating diabetes comprising administering to a patient in need thereof the acylated derivative of human insulin analogue or a zinc complex thereof according to claim 1 in combination with fast-acting insulin.

### Claim 19 (depends on 13)

A method for treating diabetes comprising administering to a patient in need thereof the pharmaceutical composition according to claim 13.

### Claim 20 (depends on 13)

A method for treating diabetes comprising administering to a patient in need thereof the pharmaceutical composition according to claim 13 in combination with fast-acting insulin.
